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H I G H L I G H T S
• Ketamine dose-dependently increases TrkB signaling in the cortex.• Sedative-anesthetic doses of 6,6-d2-ketamine increase TrkB phosphorylation.• Slow EEG oscillations correlate with ketamine-induced TrkB signaling.• cis-HNK produces negligible acute effects on slow oscillations and TrkB signaling.








A B S T R A C T
Subanesthetic rather than anesthetic doses are thought to bring the rapid antidepressant effects of the NMDAR
(N-methyl-D-aspartate receptor) antagonist ketamine. Among molecular mechanisms, activation of BDNF re-
ceptor TrkB along with the inhibition of GSK3β (glycogen synthase kinase 3β) are considered as critical mo-
lecular level determinants for ketamine's antidepressant effects. Hydroxynorketamines (2R,6R)-HNK and
(2S,6S)–HNK), non-anesthetic metabolites of ketamine, have been proposed to govern the therapeutic effects of
ketamine through a mechanism not involving NMDARs. However, we have shown that nitrous oxide, another
NMDAR blocking anesthetic and a putative rapid-acting antidepressant, evokes TrkB-GSK3β signaling alterations
during rebound slow EEG (electroencephalogram) oscillations. We investigated here the acute effects of keta-
mine, 6,6-d2-ketamine (a ketamine analogue resistant to metabolism) and cis-HNK that contains (2R,6R) and
(2S,6S) enantiomers in 1:1 ratio, on TrkB-GSK3β signaling and concomitant electroencephalographic (EEG)
alterations in the adult mouse cortex. Ketamine dose-dependently increased slow oscillations and phosphor-
ylations of TrkBY816 and GSK3βS9 in crude brain homogenates (i.e. sedative/anesthetic doses (> 50mg/kg, i.p.)
produced more prominent effects than a subanesthetic dose (10mg/kg, i.p.)). Similar, albeit less obvious, effects
were seen in crude synaptosomes. A sedative dose of 6,6-d2-ketamine (100mg/kg, i.p.) recapitulated the effects
of ketamine on TrkB and GSK3β phosphorylation while cis-HNK at a dose of 20mg/kg produced negligible acute
effects on TrkB-GSK3β signaling or slow oscillations. These findings suggest that the acute effects of ketamine on
TrkB-GSK3β signaling are by no means restricted to subanesthetic (i.e. antidepressant) doses and that cis-HNK is
not responsible for these effects.
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1. Introduction
Ketamine has been in active clinical use in anesthesiology for over
half a century, but recently new interest has sparked from its ability to
rapidly and efficiently ameliorate depressive symptoms in treatment
resistant patients (Berman et al., 2000). The dissociative anesthesia
produced by ketamine is different from many other sedatives and an-
esthetics, since it is not a hypnotic drug (Sinner and Graf, 2011). Unlike
most general anesthetics, ketamine-induced blockade of the NMDARs
(N-methyl-D-aspartate receptors) leads to the emergence of dissociative
states, where patients may experience being conscious while being
drawn away from their sensory perception (Mathew and Zarate, 2016).
The level of dissociation is increased with dose, with higher doses
deepening into hallucinatory-like states of open and closed-eye visuals
and extreme perturbations of thought and bodily sensation (Garfield
et al., 1972). Ketamine dose-dependently regulates the emergence of
slow EEG oscillations (delta, ∼1–4 Hz), which coincide with the dee-
pening of anesthesia, while lower subanesthetic doses preferentially
influence high frequency gamma oscillations (25–100Hz) (Hiyoshi
et al., 2014; Maksimow et al., 2006; Purdon et al., 2015; Zanos et al.,
2016). Increased gamma oscillations are thought to be connected to the
acute psychotomimetic and excitatory effects of ketamine on cortical
neurons (Purdon et al., 2015). The effects of ketamine on delta oscil-
lations and EEG slowing in general are less pronounced than seen with
general anesthetics and sedatives acting on GABAA channels or α2-
adrenergic receptors (Kohtala et al., 2019; Maksimow et al., 2006;
Purdon et al., 2015).
Subanesthetic doses of ketamine (0.5mg/kg, over a 40-min i.v. in-
fusion) have been consistently used in clinical research and have re-
peatedly demonstrated efficacy in ameliorating depressive symptoms.
Intriguingly, some studies have reported a relationship between the
antidepressant response and the psychotomimetic effects or dissociative
symptoms produced by the higher-end of subanesthetic doses of keta-
mine (Lai et al., 2014; Loo et al., 2016; Luckenbaugh et al., 2014; Niciu
et al., 2018; Sos et al., 2013; Xu et al., 2016). Generally, higher anes-
thetic doses of ketamine are not however thought to elicit anti-
depressant effects, but doses up to 1mg/kg have been demonstrated to
be effective (Fava et al., 2018). Yet, knowledge of the dose-dependence
of ketamine's effects in both clinical and preclinical settings is in-
complete.
A large number of preclinical studies have elucidated the neuro-
pharmacological mechanisms behind ketamine's rapid-acting anti-
depressant effects. Subanesthetic doses have been proposed to increase
glutamate release either via the preferential blockade of NMDARs on
GABAergic interneurons (Homayoun and Moghaddam, 2007;
Moghaddam et al., 1997) or through direct antagonism of extrasynaptic
NMDARs on pyramidal neurons, resulting in compensatory increases of
excitatory drive in the prefrontal cortex (Miller et al., 2016). Indeed,
low doses of ketamine have been reported to increase glutamate ac-
tivity as measured by microdialysis in rats, while anesthetic doses lead
to decreases in glutamate release (Moghaddam et al., 1997). Further-
more, this surge in glutamate after subanesthetic ketamine adminis-
tration has been proposed to underlie the rapid-acting antidepressant
effects via the regulation of AMPARs (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors), since blockade of these channels
with NBQX abolishes ketamine's antidepressant like behavioral re-
sponses in mice and rats (Koike et al., 2011; Koike and Chaki, 2014;
Maeng et al., 2008). These events have been proposed to further lead
into to the activation of BDNF (brain-derived neurotrophic factor) re-
ceptor TrkB, mTOR (mammalian target of rapamycin) and p44/42-
MAPK (mitogen-activated protein kinase) signaling along with the in-
hibition of GSK3β (glycogen synthase kinase 3β), which have been
intimately connected with ketamines' antidepressant effects in mole-
cular studies and behavioral models (Beurel et al., 2011; Li et al., 2010;
Réus et al., 2014).
Recently an animal study investigating the effects of ketamine's
metabolites suggested that particular metabolites, hydro-
xynorketamines (HNKs), are responsible for ketamine's rapid anti-
depressant effects (Zanos et al., 2016). Both (2R,6R) and (2S,6S) en-
antiomers of HNK produce antidepressant-like effects in mice, although
(2R,6R) is more effective (Zanos et al., 2016). These effects of HNK are
suggested to be produced through a more direct modulation of AMPAR
activity without the involvement of NMDARs (Zanos et al., 2016). This
hypothesis, however, contrasts with many studies emphasizing the
critical role of NMDAR antagonism as the main mechanism of ketami-
ne's action, and has subsequently raised important debate about the
neuropharmacological mechanisms involved (Collingridge et al., 2017;
Suzuki et al., 2017).
Electroconvulsive therapy (ECT) is still among the most effective
antidepressant treatments in clinical use. The ability of ECT to ame-
liorate depressive symptoms has been associated with post-ictal (i.e.
after seizure) emergence of slow EEG oscillations and/or burst sup-
pression pattern rapidly after convulsions, but also the general slowing
of the EEG during the course of the treatments (Fink and Kahn, 1957;
Folkerts, 1996; Nobler et al., 1993; Perera et al., 2004; Sackeim et al.,
1996; Suppes et al., 1996). These effects of ECT on EEG encouraged
scientists already decades ago to test whether the silencing of cortical
activity induced by general anesthetics might be sufficient enough to
elicit antidepressant responses. Some pilot clinical studies of isoflurane
and propofol for depression have indeed shown promise (Engelhardt
et al., 1993; Langer et al., 1995, 1985; Mickey et al., 2018; Weeks et al.,
2013). We have previously demonstrated that brief burst-suppressing
isoflurane anesthesia essentially regulates key molecular alterations
implicated in antidepressant mechanisms and produces antidepressant-
like behavioral outcomes in mice (Antila et al., 2017; Theilmann et al.,
2019). Similar phenotypic effects of isoflurane have been later observed
in rats by others (Brown et al., 2018). Most intriguingly, our latest study
demonstrated that subanesthetic nitrous oxide (N2O), another NMDAR
antagonist and a putative rapid-acting antidepressant (Nagele et al.,
2015), produces “rebound” cortical slow EEG oscillations after the
acute pharmacological effects have subsided along with the regulation
of TrkB-GSK3β signaling (Kohtala et al., 2019).
In the present study we investigated the dose-dependent effects of
ketamine on some of the molecular pathways heavily implicated in its
rapid-antidepressant action along with quantitative EEG to recapitulate
changes on cortical brain activity. Moreover, we used 6,6-dideuter-
oketamine (a ketamine analogue resistant to metabolism) along with
cis-HNK that contains (2R,6R) and (2S,6S) enantiomers in 1:1 ratio to
gain further insight into the mechanistic basis of such molecular al-
terations regulated by ketamine.
2. Methods and materials
2.1. Animals
Adult male C57BL/6JRccHsd mice (Harlan Laboratories, Venray,
The Netherlands) were used. Animals were maintained in the animal
facility of University of Helsinki (Finland) under standard conditions
(21 °C, 12-h light-dark cycle) with free access to food and water. The
animal experiments were carried out according to the guidelines of the
Society for Neuroscience and were approved by the County
Administrative Board of Southern Finland (License: ESAVI/10527/
04.10.07/2014).
2.2. EEG recordings and data analysis
For the implantation of electrodes, mice were anesthetized with
isoflurane (3% induction, 1.5–2% maintenance). Lidocaine (10mg/mL)
was used as local anesthetic and buprenorphine (0.1mg/kg, s.c.) for
postoperative care. Two epidural screw EEG (electroencephalogram)
electrodes were placed above the fronto-parietal cortex. A further screw
served as mounting support. Two silver wire electrodes were implanted
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in the nuchal muscles to monitor the EMG (electromyogram). After the
surgery, mice were single-housed in Plexiglas boxes. After a recovery
period of 5–7 days, animals were connected to flexible counterbalanced
cables for EEG/EMG recording and habituated to recording cables for
three days.
Baseline EEG (10–15min) recordings of awake animals were con-
ducted prior i.p. injection of saline or test compound. All recordings
were performed during the light period.
The EEG and EMG signals were amplified (gain 5 or 10 K) and fil-
tered (high pass: 0.3 Hz; low pass 100 Hz; notch filter) with a 16-
channel AC amplifier (A-M System, model 3500), sampled at 254 Hz or
70 Hz with 1401 unit (CED), and recorded using Spike2 (version 8.07,
Cambridge Electronic Devices). The processing of the EEG data was
obtained using Spike2 (version 8.07, Cambridge Electronic Devices).
EEG power spectra were calculated within the 1–50Hz frequency range
by fast Fourier transform (FFT= 256, Hanning window, 1.0 Hz re-
solution). Oscillation power in each bandwidth (delta= 1–4Hz;
theta= 4–7 Hz; alpha=7–12 Hz; beta= 12–25 Hz; gamma
low=25–40 Hz; gamma high=60–100 Hz) was computed in 30-300-
sec epochs from spectrograms (FFT size: 1024 points) for each animal.
Representative sonograms were computed using a Hanning window
with a block size of 512.
2.3. Pharmacological treatments
All drug treatments were done during the light phase between
9:00–12:00 a.m. Ketamine-HCl (10–200mg/kg; Ketaminol®, Intervet
International B.V.), 6,6-d2-ketamine-HCl (see below; 100mg/kg) and
cis-6-hydroxynorketamine-HCl (10–20mg/kg; Tocris) were diluted in
isotonic saline solution and injected intraperitoneally with an injection
volume of 10mL/kg.
2.4. Synthesis of 6,6-d2-ketamine-HCl
Reagents and solvents for the syntheses were purchased from Sigma-
Aldrich (Darmstadt, Germany) and VWR International Oy (Helsinki,
Finland). Racemic ketamine hydrochloride was purchased from YA
Apteekki (Helsinki, Finland). 1H NMR and 13C NMR spectra in CDCl3 or
CD3OD at ambient temperature were recorded on a Bruker Avance
400MHz NMR (Bruker Corporation, Billerica, MA, USA) with the smart
probe. Chemical shifts (δ) are given in parts per million (ppm) relative
to the NMR reference solvent signals (CDCl3: 7.26 ppm; CD3OD:
3.31 ppm for 1H NMR and CDCl3: 77.16 ppm; CD3OD: 49.0 ppm for 13C
NMR). Multiplicities are indicated by s (singlet), br s (broad singlet), d
(doublet), dd (doublet of doublets), ddd (doublet of doublet of doub-
lets), t (triplet), m (multiplet). The coupling constants J are quoted in
Hertz (Hz). HRMS spectra were recorded using Waters Acquity UPLC®-
system (Waters, Milford MA, USA) with Acquity UPLC® BEH C18
column (1.7 μm, 50 mm × 2.1 mm, Waters, Wexford, Ireland) with
Waters Synapt G2 HDMS (Waters, Milford MA, USA) with the ESI (+),
high resolution mode. The mobile phase consisted of H2O (A) and
acetonitrile (B) both containing 0.1% HCOOH. Microwave syntheses
were performed in sealed tubes using Biotage Initiator + instrument
(Uppsala, Sweden) equipped with an external IR sensor.
2.4.1. Synthesis of 6,6-d2-ketamine-HCl 3 (1)
Racemic ketamine-HCl 1 (0.60 g, 2.2mmol (YA Apteekki, Helsinki,
Finland) was dissolved in dry tetrahydrofuran (6mL) and D2O
(2.25mL). To this solution a 40% solution of NaOD in D2O (2.25mL)
was added. The sealed tube was microwave-irradiated at 120 °C for 2 h.
The resulting mixture was poured to 1M aqueous solution of HCl
(20mL). The white precipitate was filtered and washed with water and
dried to yield 2 (394mg, 75%). 1H NMR and MS spectra showed that
the isotopic purity was not over 90%, so the above procedure was re-
peated for 2 (379mg) using a 40% solution of NaOD in D2O (1mL). 6,6-
d2-Ketamine 2 was obtained as a white solid (342mg, 90%). 1H NMR
(400MHz, CDCl3) δ 7.55 (dd, J=7.9, 1.7 Hz, 1H), 7.38 (dd, J=7.8,
1.5 Hz, 1H), 7.32 (ddd, J=7.8, 7.3, 1.5 Hz, 1H), 7.27–7.21 (m, 1H),
2.84–2.73 (m, 1H), 2.15 (bs, 1H), 2.10 (s, 3H), 2.03–1.95 (m, 1H),
1.90–1.80 (m, 1H), 1.74 (m, 3H). 13C NMR (101MHz, CDCl3) δ 209.5,
137.9, 134.0, 131.4, 129.6, 128.8, 126.8, 70.4, 39.1 (m), 38.8, 29.3,
28.2, 22.0.
6,6-d2-Ketamine 2 (0.30 g was dissolved in dry 1,4-dioxane (5mL)
and a 4M solution of HCl in 1,4-dioxane (1mL) was added. The formed
white precipitate was filtered and dried to yielding 6,6-d2-ketamine-HCl 3
(0.26 g, 75%). 3 was dissolved to water, filtered and dried prior the use.
1H NMR (400MHz, CD3OD) δ 7.94–7.90 (m, 1H), 7.68–7.58 (m,
3H), 3.42–3.34 (m, 1H), 2.39 (s, 3H), 2.17–2.10 (m, 1H), 1.96–1.84 (m,
2H), 1.83–1.68 (m, 2H), 13C NMR (101MHz, CD3OD) δ 208.4, 135.9,
133.9, 133.4, 133.2, 129.7, 129.2, 73.6, 40.3 (m), 37.4, 30.9, 27.9,
22.8. 1H NMR and 13C NMR were in agreement with reported data
(Zanos et al., 2016). HRMS (ESI+): Calcd for C13H15D2ClNO+
240.1124; found 240.1130.
2.5. Dissection and processing of brain samples
Animals were euthanized at indicated times after the treatments by
rapid cervical dislocation followed by decapitation (Kohtala et al., 2016).
Bilateral medial prefrontal cortex (including prelimbic and infralimbic
cortices) was rapidly dissected on a cooled dish and stored at −80 °C until
further processing (Rantamäki et al., 2007). For the analysis of crude
brain homogenates the samples were homogenized in lysis buffer
(137mM NaCl, 20mM Tris, 1% NP-40, 10% glycerol, 48mM NaF, H2O,
Complete inhibitor mix (Roche), PhosStop (Roche)). After ∼15-min in-
cubation on ice, samples were centrifuged (16000g, 15min, 4 °C) and the
resulting supernatant collected for Western blot analysis. For the pre-
paration of crude synaptosomes, brain samples were homogenized in 10%
(w/v) ice-cold buffer containing 0.32M sucrose, 20mM HEPES pH 7.4,
1mM EDTA, 1 X protease inhibitor cocktail (Roche, Mannheim, Ger-
many), 5mM NaF, 1mM Na3VO4, and 5mM Na2HPO4. After cen-
trifugation of the homogenate at 2800 rpm for 10min at 4 °C, the super-
natant was transferred to a new tube and centrifuged at 12 000 rpm for
10min. The supernatant (cytosolic fraction) was removed and the re-
sultant pellet, designated the crude synaptosomal fraction, was re-
suspended in lysis buffer (150mM NaCl, 50mM Tris-HCl, pH 7.4, 1%
Triton X-100, 0.1% SDS, 1 X protease inhibitor cocktail, 2mM EDTA,
5mM NaF, 1mM Na3VO4, and 5mM Na2HPO4).
2.6. Western blotting
Samples (20–50 μg protein) were separated with SDS-PAGE under
reducing and denaturing conditions and blotted to a PVDF (poly-
vinylidene difluoride) or nitrocellulose membrane using standard pro-
tocols. After blocking, the membranes were incubated with the fol-
lowing primary antibodies: anti-p-TrkBY816 (#4168; 1:250–1000, Cell
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signaling technology (CST)), anti-TrkB (#4603; 1:1000, CST or,
#AF1494; 1:500, #R&D Systems), pan-Trk (sc-11; 1:1000; Santa Cruz
Biotechnology (SCB)), anti-p-CREB (#9191S; 1:1000, CST), anti-p-
p70S6KT421/S424 (#9204S; 1:500–1000, CST), anti-p-GSK3βS9 (#9336;
1:1000, CST or #5558; 1:500, CST), anti-p-p44/42-MAPKThr202/Y204
(#9106; 1:1000, CST), anti-GSK3β (#9315; 1:1000, CST or #9832;
1:1000, CST), anti-p70S6K (#2708; 1:1000, CST), anti-p44/42-MAPK
(#9102; 1:1000, CST), anti-GAPDH (#2118; 1:10 000, CST), anti-β-
actin (926–42212; 1:3000, LI-COR), anti-Synaptotagmin 1 (ANR-003;
1:400, Alomone), anti-BDNF (ab108319; 1:1000, Abcam), anti-
NMDAR2B (#14544; 1:1000, CST), and anti-PSD95 (#2507; 1:500,
CST). Further, the membranes were washed with TBS/0.1% Tween
(TBST) and incubated with horseradish peroxidase conjugated sec-
ondary antibodies (1:10000, 1 h at room temperature; Bio-Rad) or ap-
propriate IRDye conjugated secondary antibody (1:15000,1 h at room
temperature; LI-COR): IRDye 800CW goat anti-rabbit IgG, IRDye
680RD goat anti-rabbit IgG, IRDye 800CW goat anti-mouse IgG, IRDye
680RD goat anti-mouse IgG, IRDye 800CW donkey anti-goat IgG, and
IRDye 680RD donkey anti-rabbit IgG. After subsequent washes, sec-
ondary antibodies were visualized using enhanced chemiluminescence
(ECL Plus, ThermoScientific) for detection by Biorad ChemiDoc MP
camera (Bio-Rad Laboratories) or infrared signals using the Odyssey
CLx infrared imaging system. ImageJ and Image Studio software
Version 5.0 (LI-COR) were used for quantifications of chemilumi-
nescense and fluorescense blots, respectively.
2.7. Statistical analyses
Depending on whether data were normally distributed or not, either
parametric or nonparametric tests were used for statistical evaluation.
In case of more than two groups, analysis of variance (ANOVA) with
appropriate post hoc test was used. All statistical analyses were per-
formed with the Prism 7 software from GraphPad (La Jolla, CA, USA).
All tests were used two-sided; a P≤0.05 was considered significant.
For statistical analyses and n numbers see Supplementary Table 1.
3. Results
3.1. Ketamine regulates TrkB-GSK3β signaling dose-dependently during
increased slow oscillations
Subanesthetic dose of ketamine (10mg/kg, i.p.) produced a modest
increase in gamma high oscillations (60–100 Hz), suggestive of the
acute psychopharmacological effects, while effects on other frequency
bands were limited (Fig. 1A–B). A higher dose of ketamine (100mg/kg,
i.p.), however, produced a rapid and significant increase in delta-fre-
quency (1–4 Hz) power along with increases in theta (4–7 Hz), beta
(12–25 Hz), gamma low (25–40 Hz) and gamma high power
(60–100 Hz), while decreasing alpha frequency power (7–12 Hz).
Overall, these observations are well in line with previous findings
(Hiyoshi et al., 2014; Zanos et al., 2016) and further demonstrate the
dose-dependent effects of ketamine on cortical activity measured by
EEG.
We next investigated the dose-dependent effects of ketamine on
TrkB and GSK3β phosphorylation in the medial prefrontal cortex
(mPFC). We initially focused our studies to crude homogenates since
various antidepressants have been show to regulate TrkB signaling in
such preparations (Antila et al., 2017; Aonurm-Helm et al., 2015; Autry
et al., 2011; Di Lieto et al., 2012; Dong et al., 2017; Kohtala et al., 2019;
Rantamäki et al., 2007, 2006; Saarelainen et al., 2003; Sun et al., 2016).
We saw significant increases in TrkBY816, p70S6kT421/S424 (downstream
of mTOR) and GSK3βS9 phosphorylation 30min after a high dose
(100mg/kg, i.p.) of ketamine, while a subanesthetic dose (10mg/kg,
i.p.) failed to produce any changes (Fig. 1C). Similar, albeit less pro-
nounced, effects we seen when the brain samples were collected 15min
post-injection (Fig. S1).
We next investigated the effects of ketamine on TrkB, p70S6k and
GSK3β phosphorylations in synaptosomal preparations (Fig. S2), which
have also been used to assess antidepressant-induced changes on these
molecular events. While phosphorylation of TrkBY816 remained un-
affected, phosphorylation of GSK3βS9 was increased by an anesthetic
dose of ketamine, and phosphorylation of p70S6kT421/S424 was upre-
gulated by both subanesthetic and high dose 30min post-injection (Fig.
S3). Notably, no clear dose-dependent effects of ketamine were seen in
these analyses (Fig. S3).
To confirm the dose-dependent effects of ketamine on these mole-
cular effects, we performed another study with subanesthetic (10mg/
kg, i.p.), sedative (50mg/kg, i.p.) and anesthetic (200mg/kg, i.p.)
doses of ketamine. Of selected doses only the highest produced obvious
effects on TrkBY816, p70S6kT421/S424 and GSK3βS9 phosphorylation in
crude brain homogenates 30min post-injection (Fig. 2). Since the ef-
fects of ketamine on these phosphorylation changes were readily de-
tected in crude homogenates, such preparations were also used in
subsequent studies.
3.2. Regulation of TrkB-GSK3β signaling by ketamine is independent of
hydroxynorketamines
To investigate whether HNK regulates TrkB and GSK3β signaling,
we subjected mice to acute treatments with cis-HNK that contains
(2R,6R) and (2S,6S) enantiomers in 1:1 ratio and collected tissue
samples 30min later from the mPFC. The phosphorylation of TrkBY816,
p70S6kT421/S424 and GSK3βS9 remained unaltered after an acute treat-
ment of cis-HNK (20mg/kg, i.p.) (Fig. 3A). HNK produced no clear
acute EEG alterations compared to saline treated mice (Fig. 3B–C).
High doses (> 100mg/kg, i.p.) of ketamine bring sedation within
few minutes, along with increased slow oscillations in mice (Fig. 1).
Indeed, an intraperioneal dose of 200mg/kg ketamine induced pTrkB,
p70S6k and pGSK3β levels in the mouse mPFC already within 3min
when its metabolism into HNK is likely marginal (Fig. 4A). To further
investigate whether the metabolism of ketamine to HNK is involved in
ketamine-induced regulation of TrkB-GSK3β signaling, we deuterated
ketamine at the C6 position (6,6-d2-ketamine) to hinder its metabolism
and compared this ketamine analogue to the acute effects of ketamine.
Importantly, a high dose of 6,6-d2-ketamine (100mg/kg, i.p.) essen-
tially recapitulated the phosphorylation effects of an equivalent dose of
ketamine on TrkB, p70S6K and GSK3β (Fig. 4B).
4. Discussion
Activation of BDNF receptor TrkB and inhibition of GSK3β have
been intimately associated with the mechanism of action of rapid-acting
antidepressant ketamine (Duman and Aghajanian, 2012; Rantamäki
and Yalcin, 2016). We have recently shown that nitrous oxide, another
NMDAR antagonist and a putative rapid-acting antidepressant (Nagele
et al., 2015), acutely upregulates markers of cortical excitability, fol-
lowed by a period of rebound slow EEG oscillations during which TrkB-
GSK3β alterations become evident (Kohtala et al., 2019). In addition,
we have previously shown that isoflurane anesthesia, at a dosing re-
gimen shown to bring rapid antidepressant effects in a subset of patients
(Langer et al., 1995), targets these very same signaling mechanisms
(Antila et al., 2017; Theilmann et al., 2019). The rationale to in-
vestigate isoflurane in clinical trials was based upon the idea that post-
ictal (i.e. after seizure) emergence of burst-suppression and/or elec-
trocerebral silence predicts the onset-of-action of ECT (Krystal et al.,
1995; Langer et al., 1995, 1985; Nobler et al., 1993). In contrast to ECT,
isoflurane reliably and reproducibly produces EEG burst suppression
with adequate dosing. Notably, electroconvulsive shock (an animal
model of ECT) has not been shown to rapidly activate TrkB (Hansen
et al., 2007) although it readily increases BDNF synthesis (Nibuya et al.,
1995). ECS and volatile convulsant flurothyl does, however, increase
GSK3βS9 and TrkBY816 phosphorylation gradually after seizure
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termination (Basar et al., 2013; Kang et al., 2004; Kohtala et al., 2019;
Roh et al., 2003). These changes co-incide with marked slowing of EEG
(Kohtala et al., 2019).
The present study demonstrates that ketamine regulates TrkB-
GSK3β signaling in a dose-dependent manner in the mouse prefrontal
cortex. A low subanesthetic dose of ketamine (10mg/kg, i.p.) produced
negligible acute changes in phosphorylation while it facilitated a
modest increase in gamma high oscillations (60–100Hz). A higher
subanesthetic dose (100mg/kg, i.p.) produced a significant increase in
TrkBY816, p70S6kT421/S424 and GSK3βS9 while facilitating the power of
delta-frequency (1–4 Hz) oscillations. Increases in theta (4–7 Hz), beta
(12–25 Hz), gamma low (25–40 Hz) and gamma high (60–100 Hz)
along with decreases in alpha (7–12 Hz) frequency power were also
observed with the higher dose. Dose-dependent effects of ketamine on
TrkB-GSK3β phosphorylation was confirmed in a follow up experiment,
wherein most prominent effects were seen with 200mg/kg of ketamine
Fig. 1. (A) Normalized power of major EEG
oscillations during ketamine (10 and
100mg/kg) (data analyzed in 5min bins).
Dashed vertical line indicates injection
point (0min) (B) Major EEG oscillation
frequency band power of ketamine treat-
ments represented as area under curve
(AUC) from 30min of recording. (C)
Phosphorylation of TrkBY816, GSK3βS9 and
p70S6kT421/424 in the adult mouse medial
prefrontal cortex 30 min after an i.p. injec-
tion of saline (SAL) and ketamine (K10,
10 mg/kg; K100, 100 mg/kg). Approximate
molecular weight (MW) for each protein
band of interest is given in kilodaltons
(kDa). Data are means ± S.E.M. *< 0.05,
**< 0.01, ***<0.005 (for statistical ana-
lyses and n numbers see Supplementary
Table 1).
Fig. 2. Ketamine produces dose-dependent
increases in TrkBY816, GSK3βS9 and
p70S6kT421/424 in the adult mouse medial
prefrontal cortex 30 min after an i.p. injec-
tion of saline (SAL) and ketamine (10,
10 mg/kg; 50, 50 mg/kg; 200 mg/kg). Data
are means ± S.E.M. *<0.05, **< 0.01,
***< 0.005 (for statistical analyses and n
numbers see Supplementary Table 1).
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Fig. 3. (A) Phosphorylation of TrkBY816, GSK3βS9 and p70S6kT421/424 in the adult mouse medial prefrontal cortex 30min after an i.p. injection of saline (SAL) and cis-
6-hydroxynorketamine (HNK, 20mg/kg). B) Normalized power of major EEG oscillations during HNK (20mg/kg) (data analyzed in 5min bins). Dashed vertical line
indicates injection point (0min) (C)Major EEG oscillation frequency band power of HNK treatment represented as area under curve (AUC) from 30 min of recording.
Data are means ± S.E.M. *<0.05, **< 0.01, ***< 0.005 (for statistical analyses and n numbers see Supplementary Table 1).
Fig. 4. A) Ketamine produces increases in TrkBY816, GSK3βS9 and p70S6kT421/424 in the adult mouse medial prefrontal cortex 3min after an injection of saline (SAL)
or ketamine (KET, 200mg/kg). B) Effects of KET (100mg/kg, i.p.; 30min) and 6,6-dideuteroketamine (d-KET, 100mg/kg, i.p.; 30min) on p-TrkBY816, p-GSK3βS9
and p-p70S6kT421/424. Data are means ± S.E.M. *<0.05, **<0.01, ***<0.005 (for statistical analyses and n numbers see Supplementary Table 1).
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(i.p.). Thus, in our hands sedative/anesthetic doses of ketamine pre-
ferentially regulate TrkB-GSK3β signaling in the adult mouse brain, at
least within the selected time-frame (Lindholm et al., 2012).
One of the goals of our study was to investigate whether HNKs play
a role in the ability of ketamine to regulate TrkB and GSK3β signaling in
the brain. A recent study indicates that (2R,6R)-HNK, at a dose of
30mg/kg, increases phosphorylation of mTOR (a kinase downstream of
TrkB and upstream of p70S6k, respectively) in the mouse medial pre-
frontal cortex (Fukumoto et al., 2019). The authors did not, however,
investigate TrkB and GSK3β phosphorylation or the effects of HNK at a
dose more comparable with 10mg/kg of ketamine (Fukumoto et al.,
2019). The antidepressant effects of (2R,6R)-HNK emerge at
∼5–10mg/kg i.p. while> 25mg/kg i.p. is needed for the (2S,6S) en-
antiomer (Zanos et al., 2016). We thus selected a dose of cis-HNK that
contain 10mg/kg (2R,6R)-HNK (i.e. 20mg/kg, i.p.), a dose consistently
used by Zanos et al. and others. This dose produced negligible acute
effects on TrkB and GSK3β phosphorylation. Furthermore, we demon-
strate that a sedative dose of a deuteratated ketamine analogue (re-
sistant to metabolism) produces essentially similar effects on TrkB and
GSK3β phosphorylation as the equivalent dose of ketamine. The in-
dependence of these effects from ketamine's HNK metabolites is also
supported by altered phosphorylation levels evident already after 3min
of an anesthetic dose of ketamine. Taken together, these findings
strongly suggest that the effects of ketamine on TrkB-GSK3β signaling
are by no means restricted to subanesthetic doses and that cis-HNK is
not responsible for these effects. In contrast, the highest sedative doses
produced most obvious acute effects, which also concominantly in-
creased slow EEG oscillations. We cannot, however, rule out the pos-
sibility that HNK or its specific enantiomers, at some other doses or at
different time points, regulate TrkB-GSK3β phosphorylation. (2R,6R)-
HNK does not, however, produce sedation even at very high doses in
mice (Zanos et al., 2016).
The preferential ability of high doses of ketamine to regulate TrkB-
GSK3β signaling alterations may be related to the pharmacologically
induced brain state, evidenced by the emergence of slow oscillations
that are characteristic physiological features of deep sleep. It is thus
plausible that the phosphorylation events set forth by ketamine are
representative not only of a primary pharmacological target of the drug
and its relevant cascade of downstream effectors, but a more generally
altered brain state. This state has striking similarities with post-ictal
state and sedation, and could be the result of pronounced changes in
excitatory and/or inhibitory drive, energy metabolism, or a number of
other hypothetical mechanisms yet to be investigated. The ability of
isoflurane anesthesia (Antila et al., 2017) and medetomidine-induced
sedation (Kohtala et al., 2019) to readily and rapidly regulate TrkB-
GSK3β signaling is strictly in line with such a hypothesis.
Based on our previous findings we have proposed a hypothesis of
the two-phases of action of rapid-acting antidepressant treatments
(Kohtala et al., 2019). Essentially, we suggest that rapid-acting treat-
ments increase cortical excitability during their acute pharmacological
effects, which is followed by a homeostatic rebound increase of slow
EEG oscillations, during which the regulation of TrkB-GSK3β signaling
is also increased. While the role of slow EEG oscillations and mechan-
isms of sleep in the action of rapid-acting antidepressants remains de-
bated, several interesting perspectives have emerged. For example,
slow oscillations during subsequent night after ketamine treatment
have been found to correlate with the antidepressant efficacy (Duncan
et al., 2013), and ketamine has also been proposed to induce changes on
circadian systems (Duncan et al., 2017; Orozco-Solis et al., 2017).
Furthermore, we propose that the direct facilitation of slow EEG os-
cillations and TrkB-GSK3β signaling is not sufficient for rapid-anti-
depressant responses without the preceding cortical excitation and the
regulation of related plasticity-related immediate early genes (Kohtala
et al., 2019). Thus, the ability of higher doses of ketamine to more
prominently regulate these signaling pathways may not be directly
related to the antidepressant-like behavioral effects or clinically
meaningful antidepressant responses. Indeed, anesthetic doses of keta-
mine (> 1mg/kg, i.v.) are not considered effective againts major de-
pression and do not accelerate or improve therapeutic effects of ECT
(Carspecken et al., 2018; Järventausta et al., 2013; Rasmussen et al.,
2014) (see however Okamoto et al., 2010). Moreover, if anything, an-
tidepressant doses of ketamine (0.25–0.5mg/kg, i.v.) seem to acutely
dampen EEG oscillations within delta-theta range in both humans and
rodents (de la Salle et al., 2016; Hong et al., 2010; Kohtala et al., 2019;
Muthukumaraswamy et al., 2015; Shadli et al., 2018). Importantly
however, these effects may be time-dependent as gradual emergence of
slow EEG oscillations have been noted in animals after the acute
pharmacological effects of low-dose of ketamine have dissipated
(Feinberg and Campbell, 1995, 1993; Kohtala et al., 2019). That said,
the sequence of the appearance of these EEG alterations and molecular
signaling events, rather than the existence of these as such, may be
important for rapid antidepressant effects (Kohtala et al., 2019). Fur-
ther work in both preclinical and clinical settings is warranted to unveil
the complex dose- and time-dependent molecular and concomitant
electrophysiological alterations behind ketamine's (and its metabolites)
antidepressant effects.
5. Conclusions
Our results suggest that ketamine regulates TrkB and GSK3β sig-
naling pathways dose-dependently and independently from its HNK
metabolites. These findings further deepen the knowledge of ketamine's
effects on these molecular signaling pathways and strengthen an intri-
guing correlation between the regulation of key molecular pathways
implicated in rapid antidepressant effects and the pharmacologically
induced brain state characterized by slow oscillations and sedation,
while raising important questions about the nature of these signaling
alterations in antidepressant responses altogether.
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